Barclays
HZNP

Barclays’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Barclays’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,200
Closed -$3.84M – 5352
2023
Q1 		$3.84M Sell
35,200
-159,800
-82% -$17.7M ﹤0.01% 1730
2022
Q4 		$22.2M Buy
+195,000
New +$16.2M 0.01% 845
2020
Q4 		– Sell
-1,400
Closed -$109K – 5322
2020
Q3 		$109K Hold
1,400
– – ﹤0.01% 4211
2020
Q2 		$78K Sell
1,400
-1,800
-56% -$77K ﹤0.01% 4684
2020
Q1 		$95K Sell
3,200
-27,500
-90% -$930K ﹤0.01% 4843
2019
Q4 		$1.11M Buy
30,700
+10,000
+48% +$307K ﹤0.01% 3579
2019
Q3 		$564K Buy
20,700
+14,400
+229% +$372K ﹤0.01% 4150
2019
Q2 		$152K Sell
6,300
-3,600
-36% -$91.3K ﹤0.01% 5353
2019
Q1 		$262K Buy
9,900
+5,300
+115% +$126K ﹤0.01% 4628
2018
Q4 		$90K Sell
4,600
-1,600
-26% -$31.4K ﹤0.01% 5117
2018
Q3 		$121K Sell
6,200
-7,800
-56% -$148K ﹤0.01% 5394
2018
Q2 		$232K Buy
14,000
+7,800
+126% +$119K ﹤0.01% 4591
2018
Q1 		$88K Sell
6,200
-433,900
-99% -$6.41M ﹤0.01% 5476
2017
Q4 		$6.42M Buy
440,100
+438,300
+24,350% +$6.16M 0.01% 1471
2017
Q3 		$23K Sell
1,800
-4,300
-70% -$54.7K ﹤0.01% 5746
2017
Q2 		$72K Sell
6,100
-1,228,900
-100% -$15.3M ﹤0.01% 5131
2017
Q1 		$18.3M Sell
1,235,000
-218,700
-15% -$3.54M 0.02% 594
2016
Q4 		$23.5M Buy
+1,453,700
New +$26.4M 0.03% 524
2016
Q1 		– Sell
-286,600
Closed -$6.02M – 6616
2015
Q4 		$6.02M Buy
286,600
+214,000
+295% +$4.17M 0.01% 1195
2015
Q3 		$1.38M Buy
+72,600
New +$2.29M ﹤0.01% 2433

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's HZNP Position: Q4 2023 in Review

Barclays sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 699,553 shares — an estimated $80.9M sold.

Barclays first reported a position in HZNP in Q2 2013 and held it in 42 quarters. The position peaked at $238M in Q3 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Barclays reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Barclays sold 699,553 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $80.9M.
  • Barclays first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 42 quarters.
  • Barclays's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $238M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.